文献速递呼吸危重症与机械通气呼吸道感染

COVID-19患者接受静脉-静脉体外膜氧合治疗死亡预后因素的系统综述与荟萃分析

Prognostic factors associated with mortality among patients receiving venovenous extracorporeal membrane oxygenation for COVID-19: a systematic review and meta-analysis.
PubMed 文献 · Lancet Respir Med · 2022-10-10

年龄较大、男性、慢性肺病、症状持续时间更长、有创机械通气时间更长、动脉血二氧化碳分压更高、驱动压更高及ECMO经验较少与死亡风险增加相关,证据确定性为中或高。

要点

  • 年龄较大、男性、慢性肺病与静脉-静脉ECMO死亡风险增加相关
  • 症状持续更长、有创通气更久、PaCO2更高、驱动压更高与死亡风险增加相关
  • ECMO经验较少的中心死亡风险更高,提示患者选择与集中化的重要性

核心结论

  • 插管前患者因素、疾病因素和中心因素与COVID-19相关ARDS接受静脉-静脉ECMO患者的死亡风险相关,应纳入风险分层框架。

临床怎么用

  • 在评估COVID-19相关ARDS患者是否接受静脉-静脉ECMO时,应结合年龄、性别、慢性肺病、症状与通气时长、PaCO2、驱动压及中心经验进行风险分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Venovenous extracorporeal membrane oxygenation (ECMO) can be considered for patients with COVID-19-associated acute respiratory distress syndrome (ARDS) who continue to deteriorate despite evidence-based therapies and lung-protective ventilation. The Extracorporeal Life Support Organization has emphasised the importance of patient selection; however, to better inform these decisions, a comprehensive and evidence-based understanding of the risk factors associated with poor outcomes is necessary. We aimed to summarise the association between pre-cannulation prognostic factors and risk of mortality in adult patients requiring venovenous ECMO for the treatment of COVID-19. METHODS: In this systematic review and meta-analysis, we searched MEDLINE and Embase from Dec 1, 2019, to April 14, 2022, for randomised controlled trials and observational studies involving adult patients who required ECMO for COVID-19-associated ARDS and for whom pre-cannulation prognostic factors associated with in-hospital mortality were evaluated. We conducted separate meta-analyses of unadjusted and adjusted odds ratios (uORs), adjusted hazard ratios (aHRs), and mean differences, and excluded studies if these data could not be extracted. We assessed the risk of bias using the Quality in Prognosis Studies tool and certainty of evidence using the Grading of Recommendations Assessment, Development and Evaluation approach. Our protocol was registered with the Open Science Framework registry, osf.io/6gcy2. FINDINGS: Our search identified 2888 studies, of which 42 observational cohort studies involving 17 449 patients were included. Factors that had moderate or high certainty of association with increased mortality included patient factors, such as older age (adjusted hazard ratio [aHR] 2·27 [95% CI 1·63-3·16]), male sex (unadjusted odds ratio [uOR] 1·34 [1·20-1·49]), and chronic lung disease (aHR 1·55 [1·20-2·00]); pre-cannulation disease factors, such as longer duration of symptoms (mean difference 1·51 days [95% CI 0·36-2·65]), longer duration of invasive mechanical ventilation (uOR 1·94 [1·40-2·67]), higher partial pressure of arterial carbon dioxide (mean difference 4·04 mm Hg [1·64-6·44]), and higher driving pressure (aHR 2·36 [1·40-3·97]); and centre factors, such as less previous experience with ECMO (aOR 2·27 [1·28-4·05]. INTERPRETATION: The prognostic factors identified highlight the importance of patient selection, the effect of injurious lung ventilation, and the potential opportunity for greater centralisation and collaboration in the use of ECMO for the treatment of COVID-19-associated ARDS. These factors should be carefully considered as part of a risk stratification framework when evaluating a patient for potential treatment with venovenous ECMO. FUNDING: None.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Tran A, Fernando SM, Rochwerg B, et al. Prognostic factors associated with mortality among patients receiving venovenous extracorporeal membrane oxygenation for COVID-19: a systematic review and meta-analysis. Lancet Respir Med. 2022. PMID: 36228638. doi:10.1016/S2213-2600(22)00296-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。